AOD-9604 in Fovant — Fat Loss Peptide Research Guide
AOD-9604 research guide for Fovant. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 isn't available on pharmacy shelves in Fovant or most other cities — this is a specialist compound distributed through a dedicated online market. This global online supply model is ultimately a quality advantage — top vendors distinguish themselves through rigorous testing in ways no local retailer can match. What genuinely separates top AOD-9604 vendors is full COA coverage: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for safety screening. This guide walks Fovant researchers through that evaluation process and explains how to verify AOD-9604 vendor quality step by step.
What Studies Say About AOD-9604
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Fovant comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
AOD-9604 Purchasing Guide
Quality AOD-9604 sourcing begins with a useful first test: does this vendor make batch-matched COAs available before purchase? Suppliers that publish proactively are signalling genuine quality commitment. Mass spectrometry in the COA verifies that the main HPLC peak is actually AOD-9604 and not another compound with similar chromatographic behaviour — HPLC purity alone does not confirm what the compound actually is. For Fovant researchers evaluating new suppliers: a modest first purchase to test the product before placing larger orders is the accepted approach among experienced researchers. For Fovant researchers making a first AOD-9604 purchase: work through this evaluation framework first, order conservatively at first, and verify batch traceability on arrival before use.
Order AOD-9604 — ships to Fovant
COA-verified · International tracking · Research grade
AOD-9604 is sold for research purposes only and is not approved for human consumption by the FDA or comparable health authorities — all information here is provided for educational purposes. Lyophilised AOD-9604 should be stored frozen (−20°C) immediately upon receipt; repeated freeze-thaw cycles of reconstituted material should be avoided by aliquoting into single-use portions. Verify the endotoxin level in your AOD-9604 batch COA before use in any in-vivo protocol — look for results expressed as EU/mg or EU/mL and confirm they fall within appropriate thresholds. For any individual considering AOD-9604 outside a formal research context: consult a qualified physician — this compound is not approved for human use and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
